Compare BXSL & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BXSL | RGEN |
|---|---|---|
| Founded | 2018 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 8.2B |
| IPO Year | N/A | N/A |
| Metric | BXSL | RGEN |
|---|---|---|
| Price | $27.34 | $162.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | $29.38 | ★ $174.90 |
| AVG Volume (30 Days) | ★ 1.5M | 681.2K |
| Earning Date | 11-10-2025 | 10-28-2025 |
| Dividend Yield | ★ 11.20% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.66 | 0.03 |
| Revenue | ★ $1,413,784,000.00 | $707,890,000.00 |
| Revenue This Year | $9.05 | $17.84 |
| Revenue Next Year | $0.28 | $12.57 |
| P/E Ratio | ★ $10.35 | $6,198.22 |
| Revenue Growth | 10.58 | ★ 11.74 |
| 52 Week Low | $24.85 | $102.97 |
| 52 Week High | $34.64 | $182.52 |
| Indicator | BXSL | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 44.93 | 53.78 |
| Support Level | $28.03 | $156.01 |
| Resistance Level | $28.59 | $165.02 |
| Average True Range (ATR) | 0.43 | 4.65 |
| MACD | -0.11 | -1.09 |
| Stochastic Oscillator | 7.14 | 41.21 |
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.